Pregabalin is a widely used gabapentinoid medicine indicated in many jurisdictions for neuropathic pain, fibromyalgia, partial-onset seizures as adjunctive therapy, and generalized anxiety disorder where approved. Its market relevance is anchored in the growing clinical burden of diabetes-related neuropathy, postherpetic neuralgia, spinal cord injury pain, epilepsy, and chronic pain syndromes, alongside increased attention to multimodal pain management and reduced reliance on opioid therapy. The pregabalin landscape is shaped by patent expirations, broad generic availability, evolving prescribing controls, pharmacovigilance requirements, and payer scrutiny of long-term use. Demand is also influenced by population aging, diabetes prevalence, expanded diagnosis of neuropathic pain, and access to primary care, neurology, psychiatry, and pain management services. However, industry participants must navigate safety concerns, including dizziness, somnolence, edema, weight gain, respiratory depression risks when combined with central nervous system depressants, and misuse potential that has prompted tighter scheduling or monitoring in several countries. For stakeholders across active pharmaceutical ingredients, finished dosage forms, distribution, and clinical care pathways, success increasingly depends on quality assurance, regulatory compliance, responsible promotion, real-world evidence, and patient-centered adherence support.

Transformative Shifts in the Pregabalin Landscape

The pregabalin landscape is undergoing structural change as healthcare systems balance access to effective neuropathic pain and seizure therapies with stronger controls on inappropriate use. Genericization has intensified price competition and broadened availability, making manufacturing efficiency, bioequivalence reliability, supply continuity, and differentiated formulations more important than brand recognition. Regulatory agencies and clinical guideline bodies are also reshaping utilization by emphasizing careful patient selection, dose titration, renal-dose adjustment, tapering strategies, and monitoring for dependence or misuse. In parallel, pain care is moving toward integrated pathways that combine pharmacological therapy with physical rehabilitation, psychological support, diabetes management, and digital follow-up. Pharmacies and prescribers are increasingly expected to identify high-risk combinations, particularly concurrent use with opioids, benzodiazepines, alcohol, or other sedatives. Another major shift is the growing role of real-world evidence, as payers and health systems examine persistence, adverse events, switching behavior, and outcomes across diverse patient groups. These changes are pushing industry leaders to move beyond volume-led strategies and focus on responsible access, supply chain resilience, evidence generation, and compliance-led commercialization.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing the pregabalin value chain, from drug safety monitoring to manufacturing quality and clinical decision support. In pharmacovigilance, AI-enabled natural language processing can help screen adverse event reports, medical literature, electronic health records, and call-center narratives for signals related to sedation, falls, respiratory depression, misuse, withdrawal symptoms, and drug interactions. In manufacturing, machine learning can support process analytical technology, batch deviation detection, predictive maintenance, and quality trend analysis for active pharmaceutical ingredient and finished dosage production. In clinical settings, AI-assisted tools may help identify patients with neuropathic pain patterns, flag renal impairment requiring dose adjustment, and detect high-risk co-prescribing combinations. AI can also strengthen adherence analytics by using pharmacy refill patterns and digital health engagement to identify patients at risk of discontinuation or unsafe escalation. The cumulative impact is not simply automation; it is the creation of faster, more auditable systems for safety, compliance, and patient support. Nevertheless, implementation must be governed by validated datasets, privacy protections, explainable models, and clinical oversight to avoid bias, inappropriate prescribing prompts, or overreliance on algorithmic recommendations.

Key Regional Insights

In Asia-Pacific, pregabalin adoption is supported by large patient populations, rising diabetes burden, expanding generic manufacturing capacity, and growing access to neurology and pain services, with China, India, Japan, South Korea, and Australia demonstrating distinct regulatory and reimbursement pathways. North America remains highly shaped by controlled-substance frameworks, payer utilization management, opioid-sparing pain strategies, and strong pharmacovigilance expectations, particularly in the United States and Canada where prescribing data, dispensing oversight, and risk communication influence utilization. Latin America is characterized by improving access to generic medicines and increasing recognition of neuropathic pain, though affordability, fragmented healthcare delivery, and uneven specialist access continue to affect treatment continuity. Europe reflects mature regulatory oversight, extensive generic competition, and national-level guidance on gabapentinoid prescribing, with several countries tightening controls because of misuse and dependence concerns. The Middle East shows expanding access through hospital systems, specialist clinics, and government procurement channels, while prescribing practices are influenced by controlled medicine policies and variability in insurance coverage. Africa presents a more uneven landscape, where pregabalin availability depends on essential medicine procurement priorities, private-sector access, local registration status, affordability, and clinician capacity to diagnose and manage neuropathic pain and epilepsy. Across all regions, the most durable opportunities are linked to quality-assured generics, responsible distribution, patient education, and alignment with national medicine safety policies.

Key Group Insights

Within ASEAN, pregabalin dynamics are shaped by diverse regulatory maturity, expanding diabetes care, growing private healthcare access, and an active generic medicines environment, with affordability and consistent supply remaining central to adoption. The GCC countries benefit from strong hospital infrastructure, centralized procurement, and increasing specialty care capacity, while strict controlled medicine rules and formulary decisions guide availability and prescribing behavior. In the European Union, harmonized regulatory standards coexist with country-specific reimbursement and prescribing controls, creating a landscape where pharmacovigilance, bioequivalence, serialization, and responsible use policies are essential competitive requirements. BRICS countries collectively represent a broad range of pregabalin demand drivers, including large neuropathic pain and epilepsy patient pools, domestic pharmaceutical manufacturing capabilities, expanding insurance coverage, and variable enforcement of prescription controls. G7 markets are characterized by advanced regulatory oversight, widespread generic penetration, mature pharmacovigilance systems, and strong payer focus on appropriate prescribing, particularly for chronic pain populations and patients using concomitant sedatives. NATO member countries overlap substantially with regulated North American and European markets, where medicine security, supply chain resilience, quality compliance, and controlled-substance governance are increasingly relevant to pharmaceutical procurement and continuity planning. Across these groups, the common strategic theme is the shift from basic product availability toward evidence-backed, quality-led, and safety-conscious pregabalin access.

Key Country Insights

In the United States, pregabalin use is shaped by generic availability, state-level monitoring, payer prior authorization, and heightened awareness of gabapentinoid risks when combined with opioids or other sedatives. Canada similarly emphasizes controlled access, prescription monitoring in multiple provinces, and careful prescribing for chronic pain and seizure-related indications. Mexico and Brazil demonstrate growing generic access and a significant need for neuropathic pain treatment, particularly in diabetes-related complications, although affordability and healthcare fragmentation influence continuity of therapy. The United Kingdom has placed pregabalin under stricter controlled drug scheduling, making safe prescribing, tapering, and misuse prevention central to clinical practice. Germany, France, Italy, and Spain operate within mature European regulatory and reimbursement systems where generic competition is strong and prescribing guidance increasingly emphasizes risk assessment and appropriate duration of therapy. Russia has demand drivers linked to neurology, pain management, and epilepsy care, with access shaped by domestic registration, procurement, and pricing policies. China combines a large patient base with expanding domestic pharmaceutical production and evolving volume-based procurement mechanisms that place strong pressure on quality and cost efficiency. India is a major generic manufacturing hub with broad domestic use, while prescription discipline and pharmacovigilance maturity remain important areas of policy attention. Japan maintains rigorous regulatory standards and an aging population with neuropathic pain needs, supporting demand for clinically well-characterized therapies. Australia regulates pregabalin through national reimbursement and prescribing controls, with attention to misuse, dependence, and co-prescribing risks. South Korea combines advanced healthcare infrastructure, strong insurance coverage, and high expectations for quality, bioequivalence, and post-marketing safety monitoring. Across these countries, industry performance depends on regulatory readiness, supply reliability, evidence-based positioning, and support for responsible clinical use.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize responsible access strategies that align commercial growth with patient safety and regulatory expectations. First, strengthen pharmacovigilance systems to capture misuse, dependence, withdrawal, respiratory depression, falls, and high-risk co-prescribing signals in near real time. Second, invest in manufacturing excellence, including robust supplier qualification, impurity control, bioequivalence consistency, serialization compliance, and resilient sourcing for active pharmaceutical ingredients. Third, support prescriber and pharmacist education focused on renal dosing, gradual titration, tapering, interaction risks, and patient counseling. Fourth, develop real-world evidence programs that evaluate adherence, treatment persistence, safety outcomes, and patient-reported pain or function improvements without making unsupported comparative claims. Fifth, tailor access strategies to local reimbursement rules, controlled-substance requirements, and formulary evidence expectations. Sixth, use digital tools responsibly to improve medication reminders, refill coordination, and adverse event reporting while protecting patient privacy. Finally, prepare for increased regulatory scrutiny by maintaining transparent documentation, compliant promotional practices, and proactive engagement with healthcare stakeholders on safe and appropriate pregabalin use.

Research Methodology

This executive summary is developed using a structured secondary research approach grounded in verified public-domain and industry-relevant sources. Inputs include regulatory agency communications, prescribing information, medicine scheduling updates, pharmacovigilance advisories, clinical practice guidelines, peer-reviewed literature, public health statistics on diabetes, neuropathic pain and epilepsy, and healthcare access indicators. Regional, group, and country insights are synthesized through comparative assessment of regulatory frameworks, generic medicine policies, reimbursement practices, controlled-substance rules, healthcare infrastructure, and disease burden indicators. The analysis excludes market sizing, market share, revenue estimation, and forecasting, and instead focuses on qualitative and evidence-backed factors influencing pregabalin availability, utilization, safety, and strategic positioning. Data points are interpreted through triangulation across multiple credible sources to reduce single-source bias, with emphasis on consistency, recency, and relevance to pharmaceutical decision-making. The methodology also considers real-world constraints such as affordability, supply chain reliability, prescriber behavior, pharmacy controls, and patient adherence. This approach provides a practical, compliance-aware view of the pregabalin landscape for executives, strategists, manufacturers, distributors, and healthcare stakeholders.

Conclusion

Pregabalin remains an important therapy across neuropathic pain, epilepsy-related adjunctive treatment, fibromyalgia, and anxiety-related indications where approved, but its future is defined by responsible utilization rather than simple expansion. Generic availability has improved access, yet safety concerns, misuse potential, payer controls, and evolving prescribing guidelines require disciplined participation. Regional and country differences in regulation, reimbursement, healthcare infrastructure, and disease burden create varied pathways for adoption, making localized strategy essential. Artificial intelligence is set to strengthen pharmacovigilance, manufacturing quality, and clinical support, provided that governance, validation, and privacy safeguards are embedded from the outset. The most resilient industry leaders will be those that combine reliable supply, quality manufacturing, evidence generation, compliant engagement, and patient safety initiatives. In a landscape where regulators, payers, clinicians, and patients are increasingly focused on measurable value and harm reduction, pregabalin strategies must be built around trust, transparency, and clinically appropriate access.

Product Code: MRR-957C47F916B3

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pregabalin Market, by Dosage Form

7.1. Introduction
7.2. Capsule
7.3. Oral Solution

8. Pregabalin Market, by Drug Class

8.1. Introduction
8.2. Anticonvulsants
8.3. Fibromyalgia Agents
8.4. Neuropathic Pain Therapeutics

9. Pregabalin Market, by Distribution Channel

9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies

10. Pregabalin Market, by Application

10.1. Introduction
10.2. Epilepsy
10.3. Fibromyalgia
10.4. Generalized Anxiety Disorder
10.5. Neuropathic Pain

11. Pregabalin Market, by End User

11.1. Introduction
11.2. Home Care Settings
11.3. Hospitals
11.4. Specialty Clinics

12. Pregabalin Market, by Region

12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa

13. Pregabalin Market, by Group

13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO

14. Pregabalin Market, by Country

14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea

15. Competitive Landscape

15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
- 15.3.1. Concentration Ratio (CR)
- 15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025

16. Company Profiles

16.1. Alembic Pharmaceuticals Limited
16.2. Almelo Private Limited
16.3. Amneal Pharmaceuticals LLC
16.4. Apotex Inc.
16.5. Aurobindo Pharma Limited
16.6. BAL Pharma Ltd.
16.7. Cipla Limited
16.8. Hetero Healthcare Limited
16.9. Hikal Limited
16.10. Indoco Remedies Ltd.
16.11. Intas Pharmaceuticals Ltd.
16.12. Jiangxi Jinfeng Pharmaceutical Co., Ltd.
16.13. Jubilant Generics Limited
16.14. Lupin Limited
16.15. Medley Pharmaceuticals Ltd.
16.16. MSN Laboratories
16.17. Mylan N.V.
16.18. Novartis AG
16.19. Pfizer Inc.
16.20. Strides Pharma Science Limited
16.21. Sun Pharmaceutical Industries Ltd.
16.22. Suzhou Lixin Pharmaceutical Co., Ltd.
16.23. Teva Pharmaceutical Industries Ltd.
16.24. Unichem Laboratories Ltd.
16.25. Zydus Lifesciences Limited

Product Code: MRR-957C47F916B3

LIST OF FIGURES

FIGURE 1. GLOBAL PREGABALIN MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL PREGABALIN MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL PREGABALIN MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL PREGABALIN MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL PREGABALIN MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
FIGURE 7. GLOBAL PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PREGABALIN MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 9. GLOBAL PREGABALIN MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 11. GLOBAL PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PREGABALIN MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL PREGABALIN MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL PREGABALIN MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL PREGABALIN MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL PREGABALIN MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL PREGABALIN MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL PREGABALIN MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL PREGABALIN MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL PREGABALIN MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL PREGABALIN MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL PREGABALIN MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL PREGABALIN MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

TABLE 1. GLOBAL PREGABALIN MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL PREGABALIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CAPSULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CAPSULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ORAL SOLUTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ORAL SOLUTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ORAL SOLUTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL FIBROMYALGIA AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL FIBROMYALGIA AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL FIBROMYALGIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL NEUROPATHIC PAIN THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL NEUROPATHIC PAIN THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL NEUROPATHIC PAIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL EPILEPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL EPILEPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL EPILEPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL FIBROMYALGIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL FIBROMYALGIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL FIBROMYALGIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL NEUROPATHIC PAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL NEUROPATHIC PAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL NEUROPATHIC PAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL PREGABALIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL PREGABALIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. ASIA-PACIFIC PREGABALIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. ASIA-PACIFIC PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 56. ASIA-PACIFIC PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 57. ASIA-PACIFIC PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 58. ASIA-PACIFIC PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 59. ASIA-PACIFIC PREGABALIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 60. NORTH AMERICA PREGABALIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. NORTH AMERICA PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 62. NORTH AMERICA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 63. NORTH AMERICA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 64. NORTH AMERICA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 65. NORTH AMERICA PREGABALIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 66. LATIN AMERICA PREGABALIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. LATIN AMERICA PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 68. LATIN AMERICA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 69. LATIN AMERICA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 70. LATIN AMERICA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 71. LATIN AMERICA PREGABALIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 72. EUROPE PREGABALIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. EUROPE PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 74. EUROPE PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 75. EUROPE PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 76. EUROPE PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 77. EUROPE PREGABALIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 78. MIDDLE EAST PREGABALIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. MIDDLE EAST PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 80. MIDDLE EAST PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 81. MIDDLE EAST PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 82. MIDDLE EAST PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 83. MIDDLE EAST PREGABALIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 84. AFRICA PREGABALIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. AFRICA PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 86. AFRICA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 87. AFRICA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 88. AFRICA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 89. AFRICA PREGABALIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL PREGABALIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. ASEAN PREGABALIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. ASEAN PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 93. ASEAN PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 94. ASEAN PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 95. ASEAN PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 96. ASEAN PREGABALIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 97. GCC PREGABALIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GCC PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 99. GCC PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 100. GCC PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 101. GCC PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 102. GCC PREGABALIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 103. EUROPEAN UNION PREGABALIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. EUROPEAN UNION PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 105. EUROPEAN UNION PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 106. EUROPEAN UNION PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 107. EUROPEAN UNION PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 108. EUROPEAN UNION PREGABALIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 109. BRICS PREGABALIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 110. BRICS PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 111. BRICS PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 112. BRICS PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 113. BRICS PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 114. BRICS PREGABALIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 115. G7 PREGABALIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. G7 PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 117. G7 PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 118. G7 PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 119. G7 PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 120. G7 PREGABALIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 121. NATO PREGABALIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 122. NATO PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 123. NATO PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 124. NATO PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 125. NATO PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 126. NATO PREGABALIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL PREGABALIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 128. UNITED STATES PREGABALIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 129. UNITED STATES PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 130. UNITED STATES PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 131. UNITED STATES PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 132. UNITED STATES PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 133. UNITED STATES PREGABALIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 134. CANADA PREGABALIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 135. CANADA PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 136. CANADA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 137. CANADA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 138. CANADA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 139. CANADA PREGABALIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 140. MEXICO PREGABALIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 141. MEXICO PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 142. MEXICO PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 143. MEXICO PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 144. MEXICO PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 145. MEXICO PREGABALIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 146. BRAZIL PREGABALIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 147. BRAZIL PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 148. BRAZIL PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 149. BRAZIL PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 150. BRAZIL PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 151. BRAZIL PREGABALIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 152. UNITED KINGDOM PREGABALIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 153. UNITED KINGDOM PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 154. UNITED KINGDOM PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 155. UNITED KINGDOM PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 156. UNITED KINGDOM PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 157. UNITED KINGDOM PREGABALIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 158. GERMANY PREGABALIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 159. GERMANY PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 160. GERMANY PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 161. GERMANY PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 162. GERMANY PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 163. GERMANY PREGABALIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 164. FRANCE PREGABALIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 165. FRANCE PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 166. FRANCE PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 167. FRANCE PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 168. FRANCE PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 169. FRANCE PREGABALIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 170. RUSSIA PREGABALIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 171. RUSSIA PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 172. RUSSIA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 173. RUSSIA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 174. RUSSIA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 175. RUSSIA PREGABALIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 176. ITALY PREGABALIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 177. ITALY PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 178. ITALY PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 179. ITALY PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 180. ITALY PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 181. ITALY PREGABALIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 182. SPAIN PREGABALIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 183. SPAIN PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 184. SPAIN PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 185. SPAIN PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 186. SPAIN PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 187. SPAIN PREGABALIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 188. CHINA PREGABALIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 189. CHINA PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 190. CHINA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 191. CHINA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 192. CHINA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 193. CHINA PREGABALIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 194. INDIA PREGABALIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 195. INDIA PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 196. INDIA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 197. INDIA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 198. INDIA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 199. INDIA PREGABALIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 200. JAPAN PREGABALIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 201. JAPAN PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 202. JAPAN PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 203. JAPAN PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 204. JAPAN PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 205. JAPAN PREGABALIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 206. AUSTRALIA PREGABALIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 207. AUSTRALIA PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 208. AUSTRALIA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 209. AUSTRALIA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 210. AUSTRALIA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 211. AUSTRALIA PREGABALIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 212. SOUTH KOREA PREGABALIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 213. SOUTH KOREA PREGABALIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 214. SOUTH KOREA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 215. SOUTH KOREA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 216. SOUTH KOREA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 217. SOUTH KOREA PREGABALIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 218. GLOBAL PREGABALIN MARKET SHARE, BY KEY PLAYER, 2025
TABLE 219. GLOBAL PREGABALIN MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ

SELECT AN OPTION